Programmed death ligand 1 (PD-L1, officially known as CD274) is an immune checkpoint molecule that suppresses the immune response, and anti-PD-L1 antibodies are a mainstay of modern cancer treatment (Bellmunt et al., 2017; Brahmer et al., 2015; Motzer et al., 2018; Robert et al., 2015). This evidence concerns the gene CD274 and cancer.